CLINICAL
PATHOPHYSIOLOGY OF KIDNEY
Renal damage can impair
renal perfusion as well as glomerular and/or tubular functions. In addition,
abnormal urine composition can lead to precipitations (urolithiasis) that inhibit
the free flow of urine. Abnormal renal function can be caused by reduced renal
excretion of useless or harmful substances (e.g., uric acid, urea, creatinine,
foreign substances, and so-called uremic toxins) whose plasma concentration
then rises correspondingly. Conversely, a defective glomerular filter can lead
to renal loss of protein, while impaired tubular reabsorption can result in the
increased excretion of substances which are important for the body
(electrolytes, minerals, bicarbonate, glucose, amino acids). Reduced renal
excretory function affects the kidney’s decisive contribution to the regulation
of the metabolism of water, electrolytes, minerals, and acid–base balance.
Through its regulation of water and electrolyte metabolism the kidney is also
important for long term blood pressure regulation.
The capacity of the kidney
to regulate the composition of extracellular fluid is a function of volume,
which, per unit time, is under the control of its epithelia. For substances
that are not secreted by tubular cells, the controlled volume corresponds to
the glomerular filtration rate (GFR). All substances that are dissolved in the
filtrate can either be reabsorbed or excreted by the tubular epithelium. For
substances that are secreted by the tubular epithelium (e.g., potassium), the
controlled volume is ultimately the entire blood plasma that flows through the
kidney (renal plasma flow [RPF]).
Renal excretion is
regulated or governed by hormones (e.g., antidiuretic hormone [ADH] or [arginine] vasopressin [AVP], aldosterone, atrial
natriuretic factor [ANF), parathyroid hormone [PTH], calcitriol [1,25(OH)2
D3], calcitonin, cortisol,
prostaglandin E2, insulin, progestogens, estrogens,
thyroxine, somatotropin) and is thus adapted to requirements. Thus, disorders
of hormone release also impair renal excretory functions.
Normally the amount of
filtered water and solutes is a multiple of what is actually excreted: all of
the plasma water passes across the renal epithelia within 20 minutes; the total
extracellular volume within three hours. The excretory capacity of the kidney
is thus by no means exhausted. For this reason GFR, i.e., the volume controlled
by the kidney, can be greatly impaired without there being any harmful effect
on the body. However, a reduction in GFR will from the very beginning go hand
in hand with a diminished regulatory range that will become apparent when there
is an increased load.
The kidney is not only the
target organ for hormones, but also, by forming hormones, it influences its own
function as well as extrarenal elements of mineral metabolism (calcitriol) and
blood pressure regulation (renin/angiotensin). The prostaglandins and kinins
formed in the kidney primarily serve to regulate renal function. If the kidney
is damaged, the effects of abnormal renal excretory function are added to those
of abnormal renal excretion of hormones. The hormone erythropoietin, formed in
the kidney, regulates erythropoiesis; its absence thus causes anemia.
Lastly, the kidney
fulfills metabolic tasks. Thus, for example, in acidosis it splits ammonia from
glutamate (ammonia is excreted as NH4+) and forms glucose
from the carbohydrate skeleton (gluconeogenesis). Glucose is also formed in the
proximal tubules from absorbed lactate, and additionally fatty acids are broken
down in the tubules. The kidney plays an important role in the inactivation of
hormones. About 40% of insulin inactivation takes place in the kidney, which
also breaks down steroid hormones. Filtered oligopeptides (e.g., hormones) are
broken down in the tubular lumen and the amino acids are reabsorbed. Reduction
of functional renal tissue necessarily impairs the above-mentioned metabolic
tasks.
Pathophysiology of the
Kidney
Abnormalities of
Glomerular Function
The function of the glomeruli is to produce an
adequate GFR, i.e., the volume of plasma water that is controlled by the renal
epithelium. The selective permeability of this filter ensures the formation of
a nearly protein-free filtrate. As all of the blood flowing through the kidney
must pass through the glomerular vessels, the resistance of these vessels also
determines RPF.
The GFR is determined by the effective filtration
pressure (Peff), the hydraulic conductivity (Kf), and the filtering surface
(F): GFR=Kf· F· Peff. The effective filtration pressure is made up of the
hydrostatic (∆P) and the oncotic (∆π) pressure gradients
across the filter: Peff = ∆P – ∆π. Even if the filter is
defective, π within the capsular space of the glomerulus can be ignored,
i.e., ∆π practically equals the plasma oncotic pressure (π
cap). As a result of glomerular filtration, the protein concentration in plasma
is increased and π cap as a rule comes close to the hydrostatic pressure
gradient toward the end of the glomerular capillary loops (filtration
equilibrium).
Reduced hydraulic conductivity or a reduced filtration surface decreases the GFR. No filtration
equilibrium can be achieved; as a result of the reduced increase in π cap,
Peff ultimately rises. But this does not compensate for the reduced
conductivity.
Constriction of the vas afferens when systemic blood pressure remains constant reduces the filtration
pressure and thus the proportion of filtered plasma water (filtration fraction=
GFR/RPF). At the same time the renal blood flow and the GFR fall because of the
increased resistance.
Constriction of the vas efferens raises the effective
filtration pressure and thus also GFR/RPF. Simultaneously it reduces glomerular
perfusion and thus GFR at any given filtration fraction. The constriction of
the vas efferens (e.g., on infusion of angiotensin II) or obstruction of venous
flow (e.g., by renal vein thrombosis) can thus ultimately reduce GFR.
The glomeruli can be damaged by inflammatory disease
(glomerulonephritis). Among possible causes are soluble antigenantibody
complexes that become entangled in the glomeruli and, via complement
activation, produce local inflammation. This results in obstruction of the
glomerular capillaries and destroys the filtering function (immune complex
nephritis). Numerous drugs, allergens, and pathogens can act as antigens.
Streptococci (group A, type 12) are very often responsible. Antibodies include
IgG, IgM, and commonly IgA (IgA nephritis).
Masugi’s nephritis, caused by autoantibodies against
the basement membrane, is muchless common than immune complex nephritis. The
local inflammation initially results in hyperemia, accumulation of neutrophils
(exudative phase), and damage to the often markedly thickened basement
membrane. It is common for endothelial, mesangial, or capsular epithelial cells
to proliferate and ultimately for excess mesangial matrix to form (sclerosing).
The glomeruli may also be damaged without any local
inflammation, for example, by deposition of amyloid in amyloidosis, by a high
concentration of filtrable proteins in plasma (e.g., in multiple myeloma), by
high pressure in the glomerular capillaries (e.g., in arterial hypertension,
renal vein thrombosis, venous back pressure in right heart failure, or
hyperfiltration in diabetic nephropathy) as well as by reduced perfusion (e.g.,
in atherosclerosis, arteriosclerosis).
In glomerulonephritis, resistance in the vasa
afferentia and efferentia is increased and the RPF is reduced despite
filtration pressure usually being high. The reduced hydraulic conductivity
prevents filtration equilibrium being achieved and lowers GFR. The reduced
renal perfusion stimulates the release of rennin which, via angiotensin and
aldosterone, raises blood pressure. In addition, the development of
hypertension is aided by reduced excretion of NaCl and H2O, brought
about by the decrease in GFR.
Selective permeability is lost by damage to the
glomerular filter, thus leading to proteinuria and edema.
Damage to the kidney can, for example, destroy
erythropoietin-producing cells and thus result in the development of anemia.
Glomerular Filtration:
Vascular Resistance and Hydraulic Conductivity
Disorders of
Glomerular Permselectivity, Nephrotic Syndrome
The glomerular filter (fenestrated endothelium,
basement membrane, slit membrane between podocytes) is not equally permeable
for all blood constituents (selective permeability or permselectivity).
The glomerular filter
Molecules larger in diameter than the pores do not pass
the filter at all. Molecules of clearly smaller diameter will in practice pass
through, as will water, i.e., their concentration in the filtrate is
approximately the same as that in plasma water. If these substances are not
reabsorbed or secreted in the kidney, their clearance (C) is identical to the
GFR, and the fractional excretion (C/GFR) is 1.0. If molecules are only
slightly smaller in diameter than the diameter of the pores, only some of them
can follow water through the pores, so that their concentration in the filtrate
is lower than in plasma.
However, permeability is determined not only by the
size, but also by the charge of the molecule. Normally, negatively-charged
molecules can pass through much less easily than neutral or positively-charged
molecules. This is due to negative fixed charges that make the passage of
negatively-charged particles difficult.
In glomerulonephritis the integrity of the glomerular
filter may be impaired, In glomerulonephritis the integrity of the glomerular
filter may be impaired, and plasma proteins and even erythrocytes can gain
access to the capsular space.
Red blood cell in the
urine of the patient with glomerulonephritis (hematuria)
This results in proteinuria and hematuria. Close observation
of proteinuria indicates that it is especially the permeability for negatively
charged proteins that is increased. This behavior can be demonstrated most
impressively by infusing differently charged polysaccharides, because
polysaccharides—in contrast to proteins—are hardly reabsorbed by the tubules.
Negatively-charged (–) dextrans are normally less well filtered than neutral
(n) or cationic (+) dextrans. This selectivity is lost in glomerulonephritis
and filtration of negatively-charged dextrans is massively increased. One of
the causes of this is a breakdown of negatively-charged proteoglycans, for
example, by lysosomal enzymes from inflammatory cells that split
glycosaminoglycan. As has been shown by electrophoresis, it is especially the
relatively small, markedly negatively-charged albumins that pass across the
membrane. Even an intact glomerulus is permeable to a number of proteins that
are then reabsorbed in the proximal tubules. The transport capacity is limited,
though, and cannot cope with the excessive load of filtered protein at a
defective glomerular filter. If tubular protein reabsorption is defective
especially small proteins appear in the final urine (tubular proteinuria).
Renal loss of proteins leads to hypoproteinemia. Serum
electrophoresis demonstrates that it is largely due to a loss of albumin, while
the concentration of larger proteins actually tends to increase. This is
because the reduced oncotic pressure in the vascular system leads to increased
filtration of plasma water in the periphery and thus to a concentration of the
other blood constituents. Filtration in the peripheral capillaries is
facilitated not only by the reduced oncotic pressure, but also by damage to the
capillary wall that may also be subject to inflammatory changes. As a result of
protein filtration in the periphery, protein concentration and oncotic pressure
rise in the interstitial spaces, so that the filtration balance shifts in favor
of the interstitial space. If the removal of proteins via the lymphatics is
inadequate, edemas form.
Nephrotic syndrome
If proteinuria, hypoproteinemia, and peripheral edema
occur together, this is termed nephrotic syndrome. As the lipoproteins are not
filtered even if the filter is damaged, but hypoproteinemia stimulates the
formation of lipoproteins in the liver, hyperlipidemia results and thus also
hypercholesterolemia. It remains debatable whether a loss of glomerular
lipoprotein lipase contributes to the effect.
Hypoproteinemia favours peripheral filtration, the
loss of plasma water into the interstitial space leads to hypovolemia which
triggers thirst, release of ADH and, via renin and angiotensin, of aldosterone.
Increased water intake and increased reabsorption of sodium chloride and water
provide what is needed to maintain the edemas. As aldosterone promotes renal
excretion of K+ and H+, hypokalemia and alkalosis develop.
Abnormalities of
Glomerular Permselectivity and Nephrotic Syndrome
Edema of leds in the
patient with nephrotic syndrome
ACUTE RENAL FAILURE
Numerous and diverse disorders can lead to more or
less sudden impairment of renal function.
Acute Renal Failure – is a clinical
syndrome of
various ethiology, which is
characterized by significant and acute decrease in glomerular filtration rate (GFR). Normal GFR –
100-140 ml/mines. Acute renal insufficiency
develops, when GFR
is reduced to
1-10 ml/mines. Osmotic active substances amount is derivated which is easily excrete in volume water of
1,5-
Types of Acute Renal Failure:
Acute renal failure can
be caused by several types of conditions, including a decrease in blood flow
without ischemic injury; ischemic, toxic, or obstructive tubular injury; and
obstruction of urinary tract outflow. The causes of acute renal failure
commonly are categorized as prerenal (55% to 60%), postrenal (<5%), and
intrinsic (35% to 40%).
Causes of Acute
Renal Failure
Prerenal Failure
Prerenal failure, the
most common form of acute renal failure, is characterized by a marked decrease
in renal blood flow. It is reversible if the cause of the decreased renal
blood flow can be identified and corrected before kidney damage
occurs. Causes of prerenal failure include profound depletion of vascular
volume (e.g., hemorrhage, loss of extracellular fluid volume), impaired
perfusion caused by heart failure and cardiogenic shock, and decreased vascular
filling because of increased vascular capacity (e.g., anaphylaxis or
sepsis). Elderly persons are particularly at risk because of their
predisposition to hypovolemia and their high prevalence of renal vascular
disorders.
Some vasoactive
mediators, drugs, and diagnostic agents stimulate intense intrarenal vasoconstriction
and induce glomerular hypoperfusion and prerenal failure. Examples include
hypercalcemia, endotoxins, and radiocontrast agents such as those used for
cardiac catheterization. Many of these agents also cause acute tubular necrosis
(discussed later). In addition, several commonly used classes of drugs impair
renal adaptive mechanisms and can convert compensated renal hypoperfusion into
prerenal failure. Angiotensin-converting enzyme (ACE) inhibitors reduce the
effects of renin on renal blood flow; when combined with diuretics, they
may cause prerenal failure in persons with decreased blood flow caused by
large-vessel or small vessel renal vascular disease. Prostaglandins have a
vasodilatory effect on renal blood vessels. Nonsteroidal anti-inflammatory
drugs (NSAIDs) reduce renal blood flow through inhibition of
prostaglandin synthesis. In some persons with diminished renal perfusion,
NSAIDs can precipitate prerenal failure.
Normally, the kidneys
receive 20% to 25% of the cardiac output. This large blood supply is required
to remove metabolic wastes and regulate body fluids and electrolytes.
Fortunately, the normal kidney can tolerate relatively large reductions in
blood flow before renal damage occurs. As renal blood flow is
reduced, the GFR drops, the amount of sodium and other substances that is filtered
by the glomeruli is reduced, and the need for energy-dependent mechanisms to
reabsorb these substances is reduced. As the GFR and urine output approach
zero, oxygen consumption by the kidney approximates that required to keep renal
tubular cells alive. When blood flow falls below this level, which is
about 20% of normal, ischemic changes occur. Because of their high metabolic
rate, the tubular epithelial cells are most vulnerable to ischemic injury.
Improperly treated, prolonged renal hypoperfusion can lead to ischemic tubular
necrosis with significant morbidity and mortality.
Acute renal failure is
manifested by a sharp decrease in urine output and a disproportionate elevation
of BUN in relation to serum creatinine levels. The kidney normally responds to
a decrease in the GFR with a decrease in urine output. An early sign of
prerenal failure is a sharp decrease in urine output. BUN levels also depend on
the GFR. A low GFR allows more time for small particles such as urea to be
reabsorbed into the blood. Creatinine, which is larger and nondiffusible,
remains in the tubular fluid, and the total amount of creatinine that is filtered,
although small, is excreted in the urine. Thus, there also is a
disproportionate elevation in the ratio of BUN to serum creatinine to greater
than 20:1 (normal, approximately 10:1).
Postrenal Failure
Postrenal failure results
from obstruction of urine outflow from the kidneys. The obstruction can
occur in the ureter (i.e., calculi and strictures), bladder (i.e., tumors or
neurogenic bladder), or urethra (i.e., prostatic hypertrophy). Prostatic
hyperplasia is the most common underlying problem. Because both ureters must be
occluded to produce renal failure, obstruction of the bladder rarely causes
acute renal failure unless one of the kidneys already is damaged or a person
has only one kidney. The treatment of acute postrenal failure consists of
treating the underlying cause of obstruction so that urine flow can be
re-established before permanent nephron damage occurs.
Intrinsic
Renal Failure
Intrinsic or
intrarenal renal failure results from conditions that cause damage to
structures within the kidney—glomerular, tubular, or interstitial. Injury to
the tubules is most common and often is ischemic or toxic in origin. The major
causes of intrarenal failure are ischemia associated with prerenal failure,
toxic insult to the tubular structures of the nephron, and intratubular
obstruction. Acute glomerulonephritis and acute pyelonephritis also are
intrarenal causes of acute renal failure.
Intrinsic Renal
Failure
Intrinsic or intrarenal renal failure results from
conditions that cause damage to structures within the kidney—glomerular, tubular,
or interstitial. Injury to the tubules is most common and often is ischemic or
toxic in origin. The major causes of intrarenal failure are ischemia associated
with prerenal failure, toxic insult to the tubular structures of the nephron,
and intratubular obstruction. Acute glomerulonephritis and acute pyelonephritis
also are intrarenal causes of acute renal failure.
Acute Tubular Necrosis. Acute tubular necrosis (ATN) is characterized by destruction of tubular
epithelial cells with acute suppression of renal function.
It is the most common cause of intrinsic renal
failure. ATN can be caused by a variety of conditions, including acute tubular
damage caused by ischemia, the nephrotoxic effects of drugs, tubular
obstruction, and toxins from a massive infection. The tubular injury that
occurs in ATN frequently is reversible. The process depends on the recovery of
the injured cells, removal of the necrotic cells and intratubular casts, and
regeneration of renal cells to restore the normal continuity of the tubular
epithelium. However, if the ischemia is severe enough to cause cortical
necrosis, irreversible renal failure occurs.
Ischemic ATN occurs most frequently in persons who
have major surgery, severe hypovolemia, overwhelming sepsis, trauma, and burns.
Sepsis produces ischemia by provoking a combination of systemic vasodilation
and intrarenal hypoperfusion. In addition, sepsis results in the generation of
toxins that sensitize renal tubular cells to the damaging effects of ischemia.
ATN complicating trauma and burns frequently is multifactorial in origin and
caused by the combined effects of hypovolemia and myoglobin or other toxins
released from damaged tissue. In contrast to prerenal failure, the GFR does not
improve with the restoration of renal blood flow in acute renal failure caused
by ischemic ATN.
Nephrotoxic ATN complicates the administration of or
exposure to many structurally diverse drugs and other toxic agents. Nephrotoxic
agents cause renal injury by inducing varying combinations of renal vasoconstriction,
direct tubular damage, or intratubular obstruction. The kidney is particularly
vulnerable to nephrotic injury because of its rich blood supply and ability to
concentrate toxins to high levels in the medullary portion of the kidney. In addition,
the kidney is an important site for metabolic processes that transform
relatively harmless agents into toxic metabolites. Pharmacologic agents that
are directly toxic to the renal tubule include antimicrobial agents such as the
aminoglycosides, chemotherapeutic agents such as cisplatin and ifosfamide, and
the radiocontrast agents used during cardiac catheterization and other
diagnostic procedures. Radiocontrast media-induced nephrotoxicity is thought to
result from direct tubular toxicity and renal ischemia. The risk of renal
damage caused by radiocontrast media is greatest in elderly persons, in persons
with diabetes mellitus, and in persons who, for various reasons, are
susceptible to kidney disease. Heavy metals (e.g., lead, mercury) and organic solvents
(e.g., carbon tetrachloride, ethylene glycol) are other nephrotoxic agents.
Myoglobin, hemoglobin, uric acid, and myeloma light
chains are the most common cause of ATN attributable to intratubular
obstruction. Deposits of immunoglobulins and urine acid crystals usually are
seen in the setting of widespread malignancy or massive tumor destruction by
therapeutic agents. Hemoglobinuria results from blood transfusion reactions and
other hemolytic crises. Skeletal and cardiac muscles contain myoglobin, which
accounts for their red color. Myoglobin corresponds to hemoglobin in function,
serving as an oxygen reservoir in the muscle fibers. Myoglobin normally is not
found in the serum or urine. Myoglobinuria most commonly results from muscle
trauma but may result from extreme exertion, hyperthermia, sepsis, prolonged
seizures, potassium or phosphate depletion, and alcoholism or drug abuse. Both
myoglobin and hemoglobin discolor the urine, which may range from the color of
tea to red, brown, or black.
Types of Acute Renal Failure
The course of
acute renal failure can be divided into four
phases: the
onset or initiating phase, the oliguric phase, polyuric phase and the recovery or
convalescent phase.
The onset
or initiating phase, which lasts hours or days, is the time from the
onset of the precipitating event (e.g., ischemic phase of prerenal
failure or toxin exposure) until tubular injury occurs.
In the first
three days of acute renal failure no urine (anuria) or only a little volume of poorly
concentrated urine (oliguria) is excreted as a rule (oliguric phase). However,
urinary volume alone is a very poor indicator of the functional capacity of the
kidney in acute renal failure, because the tubular transport processes are
severely restricted and the reabsorption of filtered fluid is thus reduced.
Despite normal-looking urine volume, renal excretion of all those substances
that must normally be excreted in the urine may be markedly impaired. Inthis
case determination of the plasma and urine creatinine concentration provides
information on the true functional state of the kidneys.
Pulmonary edema in acute
renal failure
Recovery
after the oliguric phase will lead to a polyuric phase
characterized by the gradual increase of the GFR while the reabsorption function of the
epithelial nephron is still impaired (salt-losing kidney). If
the renal tubules are damaged (e.g., by heavy metals), polyuric renal failure
occurs as a primary response, i.e., large volumes of urine are excreted despite a markedly
decreased GFR.
The dangers
of acute renal failure lie in the inability of the kidney
to regulate the water and electrolyte balance. The main threat in the oliguric phase is
hyperhydration (especially with infusion of large volumes of fluid) and hyperkalemia (especially
with the simultaneous release of intracellular K+, as in burns, contusions, hemolysis,
etc.). In the polyuric phase the loss of Na+, water, HCO3–,
and especially of K+ may be so large as to be
life-threatening.
Pathogenesis of acute renal
failure
The recovery phase is the period during
which repair of renal tissue takes place.
Because of the high morbidity and mortality rates
associated with acute renal failure, identification of persons at risk is important
to clinical decision making. Acute renal failure often is reversible, making
early identification and correction of the underlying cause (e.g., improving
renal perfusion, discontinuing nephrotoxic drugs) important. Treatment includes
the judicious administration of fluids and dialysis or CRRT.
CHRONIC RENAL
FAILURE
Unlike acute renal failure, chronic renal failure represents progressive
and irreversible destruction of kidney structures. As recently as 1965, many
patients with chronic renal failure progressed to the final stages of the
disease and then died. The high mortality rate was associated with limitations
in the treatment of renal disease and with the tremendous cost of ongoing
treatment. In 1972, federal support began for dialysis and transplantation
through a Medicare entitlement program. Technologic advances in renal
replacement therapy (i.e., dialysis therapy and transplantation) have improved
the outcomes for persons with renal failure. In the
Chronic renal failure can result from a number of conditions that cause
permanent loss of nephrons, including diabetes, hypertension,
glomerulonephritis, and polycystic kidney disease. Typically, the signs and
symptoms of renal failure occur gradually and do not become evident until the
disease is far advanced. This is because of the amazing compensatory ability of
the kidneys. As kidney structures are destroyed, the remaining nephrons undergo
structural and functional hypertrophy, each increasing its function as a means
of compensating for those that have been lost. It is only when the few
remaining nephrons are destroyed that the manifestations of renal failure
become evident.
Regardless of cause, chronic renal failure results in progressive
deterioration of glomerular filtration, tubular reabsorptive capacity,
and endocrine functions of the kidneys. All forms of renal failure are
characterized by a reduction in the GFR, reflecting a corresponding
reduction in the number of functional nephrons.
Stages of Progression
The rate of nephron destruction differs from case to case, ranging from
several months to many years. The progression of chronic renal failure usually
occurs in four stages: diminished renal reserve, renal insufficiency,
renal failure, and end-stage renal disease.
The rate of nephron destruction differs from case to case, ranging from
several months to many years. The progression of chronic renal failure usually
occurs in four stages: diminished renal reserve, renal insufficiency,
renal failure, and end-stage renal disease. The rate of nephron destruction
differs from case to case, ranging from several months to many years. The
progression of chronic renal failure usually occurs in four stages: diminished
renal reserve, renal insufficiency, renal failure, and end-stage renal
disease.
Renal Failure
Renal failure develops when the GFR is less than 20%
of normal. At this point, the kidneys cannot regulate volume and solute
composition, and edema, metabolic acidosis, and hyperkalemia develop. These
alterations affect other body systems to cause neurologic, gastrointestinal,
and cardiovascular manifestations.
End-Stage Renal Disease
End-stage renal disease (ESRD) occurs when the GFR is
less than 5% of normal. Histologic findings of an end-stage kidney
include a reduction in renal capillaries and scarring in the glomeruli. Atrophy
and fibrosis are evident in the tubules. The mass of the kidneys usually
is reduced. At this final phase of renal failure, treatment with dialysis
or transplantation is necessary for survival.
Pathogenesis of
syndromes in chronic renal failure
Clinical
Manifestations
The clinical manifestations of renal failure include
alterations in water, electrolyte, and acid-base balance; mineral and skeletal
disorders; anemia and coagulation disorders; hypertension and alterations in
cardiovascular function; gastrointestinal disorders; neurologic complications;
disorders of skin integrity; and immunologic disorders. Uremia, which literally
means “urine in the blood,” is the term used to describe the clinical
manifestations of ESRD. Uremia differs from azotemia, which merely indicates
the accumulation of nitrogenous wastes in the blood and can occur without
symptoms.
There currently are four target populations that
comprise the entire population of persons with chronic renal failure: persons
with chronic renal insufficiency, those with ESRD being treated with
hemodialysis, those being treated with peritoneal dialysis, and renal
transplant recipients. The manifestations of renal failure are determined
largely by the extent of renal function that is present (e.g., renal insufficiency,
ESRD), coexisting disease conditions, and the type of renal replacement therapy
the person is receiving.
Accumulation of Nitrogenous Wastes
The accumulation of nitrogenous wastes is an early
sign of renal failure, usually occurring before other symptoms become evident.
Urea is one of the first nitrogenous wastes to accumulate in the blood,
and the BUN level becomes increasingly elevated as renal failure progresses.
The normal concentration of urea in the plasma is usually less than 20 mg/dL.
In renal failure, this level may rise to as high as 800 mg/dL.
Creatinine, a by-product of muscle metabolism, is
freely filtered in the glomerulus and is not reabsorbed in the renal tubules.
Creatinine is produced at a relatively constant rate, and any creatinine that
is filtered in the glomerulus is lost in the urine, rather than being
reabsorbed into the blood. Thus, serum creatinine can be used as an indirect
method for assessing the GFR and the extent of renal damage that has occurred
in renal failure. Because creatinine is a by-product of muscle metabolism, serum
values vary with age and muscle mass. An increase in serum creatinine to three
times its normal value suggests that there is a 75% loss of renal function, and
with creatinine levels of 10 mg/dL or more, it can be assumed that 90% of renal
function has been lost.
Disorders of Water, Electrolyte, and Acid-Base Balance
The kidneys function in the regulation of
extracellular fluid volume. They do this by either eliminating or
conserving sodium and water. Chronic renal failure can produce dehydration or fluid
overload, depending on the pathology of the renal disease. In addition to
volume regulation, the ability of the kidneys to concentrate the urine is
diminished. With early losses in renal function, the specific gravity of
the urine becomes fixed (1.008 to 1.012) and varies little from voiding
to voiding. Polyuria and nocturia are common.
As renal function declines further, the ability to
regulate sodium excretion is reduced. There is impaired ability to adjust to a
sudden reduction in sodium intake and poor tolerance of an acute sodium
overload. Volume depletion with an accompanying decrease in the GFR can occur
with a restricted sodium intake or excess sodium loss caused by diarrhea or
vomiting. Salt wasting is a common problem in advanced renal failure because of
impaired tubular reabsorption of sodium. Increasing sodium intake in persons
with chronic renal failure often improves the GFR and whatever renal function
remains. In patients with associated hypertension, the possibility of
increasing blood pressure or production of congestive heart failure often
excludes supplemental sodium intake.
Approximately 90% of potassium excretion is through
the kidneys. In renal failure, potassium excretion by each nephron increases as
the kidneys adapt to a decrease in the GFR. As a result, hyperkalemia usually
does not develop until renal function is severely compromised. Because of this
adaptive mechanism, it usually is not necessary to restrict potassium intake in
patients with chronic renal failure until the GFR has dropped below 5
mL/minute. In persons with ESRD, hyperkalemia often results from the failure to
follow dietary potassium restrictions and ingestion of medications that contain
potassium, or from an endogenous release of potassium, as in trauma or
infection.
The kidneys normally regulate blood pH by eliminating
hydrogen ions produced in metabolic processes and regenerating bicarbonate.
This is achieved through hydrogen ion secretion, sodium and bicarbonate
reabsorption, and the production of ammonia, which acts as a buffer for
titratable acids. With a decline in renal function, these mechanisms become
impaired, and metabolic acidosis results. In chronic renal failure, acidosis
seems to stabilize as the disease progresses, probably as a result of the
tremendous buffering capacity of bone. However, this buffering action is
thought to increase bone resorption and contribute to the skeletal defects
present in chronic renal failure.
Mineral Metabolism and Skeletal Disorders
Abnormalities of calcium, phosphate, and vitamin D
occur early in the course of chronic renal failure. They involve the renal
regulation of serum calcium and phosphate levels, activation of vitamin D, and
regulation of parathyroid hormone (PTH) levels.
The regulation of serum phosphate levels requires a
daily urinary excretion of an amount equal to that absorbed from the diet. With
deteriorating renal function, phosphate excretion is impaired, and as a result,
serum phosphate levels rise. At the same time, serum calcium levels fall
because serum calcium is inversely regulated in relation to serum phosphate
levels. The drop in serum calcium, in turn, stimulates PTH release, with a
resultant increase in calcium resorption from bone. Most persons with ESRD
develop secondary hyperparathyroidism, the result of chronic stimulation of the
parathyroid glands. Although serum calcium levels are maintained through
increased PTH function, this adjustment is accomplished at the expense of the
skeletal system and other body organs.
The kidneys regulate vitamin D activity by converting
the inactive form of vitamin D [25(OH) vitamin D3] to its active
form (1,25-OH2 vitamin D3). Decreased levels of active
vitamin D lead to a decrease in intestinal absorption of calcium with a
resultant increase in parathyroid hormone levels. Vitamin D also regulates
osteoblast differentiation, thereby affecting bone matrix formation and
mineralization.
Skeletal Disorders.
The term renal osteodystrophy is used to describe the skeletal complications of
ESRD. Several factors are thought to contribute to the development of renal
osteodystrophy, including elevated serum phosphate levels, decreased serum
calcium levels, impaired renal activation of vitamin D, and
hyperparathyroidism. The skeletal changes that occur with renal failure have been
divided into two major types of disorders: high-turnover and low-turnover
osteodystrophy. Inherent to both of these conditions is abnormal reabsorption
and defective remodeling of bone.
High–bone-turnover
osteodystrophy, sometimes referred to as osteitis fibrosa,
is characterized by increased bone resorption and formation, with bone
resorption predominating. The disorder is associated with secondary
hyperparathyroidism; altered vitamin D metabolism along with resistance to the
action of vitamin D; and impaired regulation of locally produced growth factors
and inhibitors. There is an increase in both osteoblast and osteoclast numbers
and activity. Although the osteoblasts produce excessive amounts of bone
matrix, mineralization fails to keep pace, and there is a decrease in bone
density and formation of porous and coarse-fibered bone. Cortical bone is
affected more severely than cancellous bone. Marrow fibrosis is another
component of osteitis fibrosa; it occurs in areas of increased bone cell
activity. In advanced stages of the disorder, cysts may develop in the bone, a
condition called osteitis fibrosa cystica.
Low–bone-turnover
osteodystrophy is characterized by decreased
numbers of osteoblasts and low or reduced numbers of osteoclasts, a low rate of
bone turnover, and an accumulation of unmineralized bone matrix. There are two
forms of low-turnover osteodystrophy: osteomalacia and adynamic osteodystrophy.
Osteomalacia, sometimes referred to as renal rickets, is characterized by a
slow rate of bone formation and defects in bone mineralization. Until the
1980s, osteomalacia in ESRD resulted mainly from aluminum intoxication.
Aluminum intoxication causes decreased and defective mineralization of bone by
existing osteoblasts and more long-term inhibition of osteoblast
differentiation. During the 1970s and 1980s, it was discovered that
accumulation of aluminum from water used in dialysis and aluminum salts used as
phosphate binders caused osteomalacia and adynamic bone disease. This discovery
led to a change in the composition of dialysis solutions and substitution of
calcium carbonate for aluminum salts as phosphate binders. As a result, the
prevalence of osteomalacia in persons with ESRD is declining.
The second type of low-turnover osteodystrophy, adynamic osteodystrophy, is
characterized by a low number of osteoblasts, the osteoclast number being
normal or reduced. In persons with adynamic bone disease, bone remodeling is
greatly reduced, and the bone surfaces become hypocellular. Adynamic bone
disease is associated with an increased fracture rate. The disease is
associated with a “relative hypothyroidism.” It has been suggested that
hypersecretion of parathyroid hormone may be necessary to maintain normal rates
of bone formation in persons with ESRD. Thus, this form of renal osteodystrophy
is seen more commonly in persons with ESRD who do not have secondary
hyperparathyroidism (i.e., those who have been treated with parathyroidectomy)
or have been overtreated with calcium and vitamin D.
The symptoms of renal osteodystrophy, which occur late
in the disease, include bone tenderness and muscle weakness. Proximal muscle
weakness in the lower extremities is common, making it difficult to get
out of a chair or climb stairs. Fractures are more common with low-turnover
osteomalacia and adynamic renal bone disease.
Early treatment of hyperphosphatemia and hypocalcemia
is important to prevent or slow long-term skeletal complications. Activated
forms of vitamin D and calcium supplements often are used to facilitate intestinal
absorption of calcium, increase serum calcium levels, and reduce parathyroid
hormone levels. Milk products and other foods high in phosphorus content are
restricted in the diet. Oral phosphate-binding agents such as calcium carbonate
may be prescribed to decrease absorption of phosphate from the gastrointestinal
tract. Aluminum-containing antacids can contribute to the development of
osteodystrophy and their use should be avoided except in acute situations.
Hematologic Disorders
Chronic anemia is the most profound hematologic
alteration that accompanies renal failure. Anemia first appears when the
GFR falls below 40 mL/minute and is present in most persons with ESRD. Several
factors contribute to anemia in persons with chronic renal failure, including a
erythropoietin deficiency, uremic toxins, and iron deficiency. The
kidneys are the primary site for the production of the hormone erythropoietin,
which controls red blood cell production. The accumulation of uremic toxins
further suppresses red cell production in the bone marrow, and the cells that
are produced have a shortened life span. Iron is essential for erythropoiesis.
Many persons receiving maintenance hemodialysis also are iron deficient because
of blood sampling and accidental loss of blood during dialysis. Other causes of
iron deficiency include factors such as anorexia and dietary restrictions
that limit intake.
When untreated, anemia causes or contributes to
weakness, fatigue, depression, insomnia, and decreased cognitive function.
There is also increasing concern regarding the physiologic effects of anemia on
cardiovascular function. The anemia of renal failure produces a decrease in
blood viscosity and a compensatory increase in heart rate. The decreased blood
viscosity also exacerbates peripheral vasodilatation and contributes to
decreased vascular resistance. Cardiac output increases in a compensatory
fashion to maintain tissue perfusion. Echocardiographic studies after
initiation of chronic dialysis have shown ventricular dilatation with compensatory
left ventricular hypertrophy. Anemia also limits myocardial oxygen supply,
particularly in persons with coronary heart disease, leading to angina pectoris
and other ischemic events. Thus, anemia, when coupled with hypertension, may be
a major contributing factor to the development of left ventricular dysfunction
and congestive heart failure in persons with ESRD.
A remarkable advance in medical management of anemia
in persons with ESRD occurred with the availability of recombinant human erythropoietin
(rhEPO). Secondary benefits of treating anemia with rhEPO, previously
attributed to the correction of uremia, include improvement in appetite, energy
level, sexual function, skin color, and hair and nail growth, and reduced cold
intolerance. Frequent measurements of hematocrit are necessary. Worsening
hypertension and seizures have occurred when the hematocrit was raised too
suddenly. Because iron deficiency is common among persons with chronic
renal failure, iron supplementation often is needed. Iron can be given orally
or intravenously. Intravenous iron may be used for treatment of persons who are
not able to maintain adequate iron status with oral iron. Bleeding disorders,
which are manifested by epistaxis, menorrhagia, gastrointestinal bleeding, and
bruising of the skin and subcutaneous tissues, are also common among persons
with chronic renal failure. Although platelet production often is normal in
ESRD, platelet function is impaired. Platelet function improves with dialysis
but does not completely normalize, suggesting that uremia contributes to the
problem. Anemia may accentuate the problem by changing the position of the
platelets with respect to the vessel wall. Normally the red cells occupy the
center of the bloodstream, and the platelets are in the skimming layer along
the endothelial surface. In anemia, the platelets become dispersed, impairing
the plateletendothelial cell adherence needed to initiate hemostasis.
Cardiovascular Disorders
Cardiovascular disorders, including hypertension, left
ventricular hypertrophy, and pericarditis, are a major cause of morbidity and
mortality in patients with ESRD. Hypertension commonly is an early
manifestation of chronic renal failure. The mechanisms that produce
hypertension in ESRD are multifactorial; they include an increased vascular
volume, elevation of peripheral vascular resistance, decreased levels of renal
vasodilator prostaglandins, and increased activity of the reninangiotensin
system. Early identification and aggressive treatment of hypertension has
been shown to slow the rate of renal impairment in many types of renal disease.
Treatment involves salt and water restriction and the use of antihypertensive
medications to control blood pressure. Many persons with renal insufficiency
need to take several antihypertensive medications to control blood pressure.
The spectrum of heart disease includes left
ventricular hypertrophy and ischemic heart disease. People with ESRD tend to
have an increased prevalence of left ventricular dysfunction, both with a
depressed left ventricular ejection fraction, as in systolic dysfunction, as
well as impaired ventricular filling, as in diastolic failure. There are
multiple factors that lead to development of left ventricular dysfunction,
including extracellular fluid overload, shunting of blood through an
arteriovenous fistula for dialysis, and anemia. These abnormalities, coupled
with the hypertension that often is present, cause increased myocardial work
and oxygen demand, with eventual development of heart failure. Coexisting
conditions that have been identified as contributing to the burden of
cardiovascular disease include anemia, diabetes mellitus, dyslipidemia, and
coagulopathies. Anemia, in particular, has been correlated with the presence of
left ventricular hypertrophy.
Pericarditis occurs in approximately 20% of persons
receiving chronic dialysis. It can result from metabolic toxins associated with
the uremic state or from dialysis. The manifestations of uremic pericarditis
resemble those of viral pericarditis, with all its complications, including
cardiac tamponade.
Gastrointestinal Disorders
Anorexia, nausea, and vomiting are common in patients
with uremia, along with a metallic taste in the mouth that further depresses
the appetite. Early-morning nausea is common. Ulceration and bleeding of the
gastrointestinal mucosa may develop, and hiccups are common. A possible cause
of nau sea and vomiting is the decomposition of urea by intestinal flora,
resulting in a high concentration of ammonia. Parathyroid hormone increases
gastric acid secretion and contributes to gastrointestinal problems. Nausea and
vomiting often improve with restriction
of dietary protein and after initiation of dialysis and disappear after kidney
transplantation.
Disorders of Neural Function
Many persons with chronic renal failure have
alterations in peripheral and central nervous system function. Peripheral
neuropathy, or involvement of the peripheral nerves, affects the lower limbs
more frequently than the upper limbs. It is symmetric and affects both sensory
and motor function. Neuropathy is caused by atrophy and demyelination of nerve fibers,
possibly caused by uremic toxins. Restless legs syndrome is a manifestation of
peripheral nerve involvement and can be seen in as many as two thirds of
patients on dialysis. This syndrome is characterized by creeping, prickling,
and itching sensations that typically are more intense at rest. Temporary
relief is obtained by moving the legs. A burning sensation of the feet, which
may be followed by muscle weakness and atrophy, is a manifestation of uremia.
The central nervous system disturbances in uremia are
similar to those caused by other metabolic and toxic disorders. Sometimes
referred to as uremic encephalopathy, the condition is poorly understood and
may result, at least in part, from an excess of toxic organic acids that alter
neural function. Electrolyte abnormalities, such as sodium shifts, also may
contribute. The manifestations are more closely related to the progress of the
uremic disorder than to the level of the metabolic end-products. Reductions in
alertness and awareness are the earliest and most significant indications
of uremic encephalopathy. This often is followed by an inability to fix
attention, loss of recent memory, and perceptual errors in identifying persons
and objects. Delirium and coma occur late in the course; seizures are the
preterminal event.
Disorders of motor function commonly accompany the
neurologic manifestations of uremic encephalopathy. During the early stages,
there often is difficulty in performing fine movements of the
extremities; the gait becomes unsteady and clumsy with tremulousness of
movement. Asterixis (dorsiflexion movements of the hands and feet)
typically occurs as the disease progresses. It can be elicited by having the
person hyperextend his or her arms at the elbow and wrist with the fingers
spread apart. If asterixis is present, this position causes side-to-side flapping
movements of the fingers.
Altered Immune Function
Infection is a common complication and cause of
hospitalization and death of patients with chronic renal failure. Immunologic
abnormalities decrease the efficiency of the immune response to infection. All
aspects of inflammation and immune function may be affected adversely by the
high levels of urea and metabolic wastes, including a decrease in granulocyte
count, impaired humoral and cell-mediated immunity, and defective phagocyte
function. The acute inflammatory response and delayed-type hypersensitivity
response are impaired. Although persons with ESRD have normal humoral responses
to vaccines, a more aggressive immunization program may be needed. Skin and
mucosal barriers to infection also may be defective. In persons who are
receiving dialysis, vascular access devices are common portals of entry for
pathogens. Many persons with ESRD do not experience fever with infection,
making the diagnosis more difficult.
Disorders of Skin Integrity
Skin manifestations are common in persons with ESRD.
The skin often is pale because of anemia and may have a sallow, yellow-brown
hue. The skin and mucous membranes often are dry, and subcutaneous bruising is
common. Skin dryness is caused by a reduction in perspiration caused by the
decreased size of sweat glands and the diminished activity of oil glands. Pruritus
is common; it results from the high serum phosphate levels and the development
of phosphate crystals that occur with hyperparathyroidism. Severe scratching
and repeated needlesticks, especially with hemodialysis, break the skin
integrity and increase the risk for infection. In the advanced stages of
untreated renal failure, urea crystals may precipitate on the skin as a result
of the high urea concentration in body fluids. The fingernails may become thin
and brittle, with a dark band just behind the leading edge of the nail,
followed by a white band. This appearance is known as Terry’s nails.
Sexual Dysfunction
Alterations in physiologic sexual responses,
reproductive ability, and libido are common. The cause probably is
multifactorial and may result from high levels of uremic toxins, neuropathy,
altered endocrine function, psychological factors, and medications (e.g.,
antihypertensive drugs).
Impotence occurs in as many as 56% of male patients
receiving dialysis. Derangements of the pituitary and gonadal hormones, such as
decreases in testosterone levels and increases in prolactin and luteinizing
hormone levels, are common and cause erectile difficulties and decreased
spermatocyte counts. Loss of libido may result from chronic anemia and
decreased testosterone levels. Several drugs, such as exogenous testosterone
and bromocriptine, have been used in an attempt to return hormone levels to
normal.
Impaired sexual function in women is manifested by
abnormal levels of progesterone, luteinizing hormone, and prolactin.
Hypofertility, menstrual abnormalities, decreased vaginal lubrication, and
various orgasmic problems have been described. Amenorrhea is common among women
who are receiving dialysis therapy.
Elimination of Drugs
The kidneys are responsible for the elimination of
many drugs and their metabolites. Renal failure and its treatment can interfere
with the absorption, distribution, and elimination of drugs. The administration
of large quantities of phosphate binding antacids to control hyperphosphatemia
and hypocalcemia in patients with advanced renal failure interferes with the
absorption of some drugs. Many drugs are bound to plasma proteins, such as
albumin, for transport in the body; the unbound portion of the drug is
available to act at the various receptor sites and is free to be metabolized. A
decrease in plasma proteins, particularly albumin, that occurs in many persons
with ESRD results in less protein-bound drug and greater amounts of free drug.
Decreased elimination by the kidneys allows drugs or
their metabolites to accumulate in the body and requires that drug dosages be
adjusted accordingly. Some drugs contain unwanted nitrogen, sodium, potassium,
and magnesium and must be avoided in patients with renal failure. For example,
penicillin contains potassium. Nitrofurantoin and ammonium chloride add to the
body’s nitrogen pool. Many antacids contain magnesium. Because of problems with
drug dosing and elimination, persons with renal failure should be cautioned against
the use of over-the-counter remedies.
Manifestations of renal
failure
CLINICAL
PATHOPHYSIOLOGY OF THE DIGESTIVE SYSTEM
Ulcer
The H+ ions in gastric juice
are secreted by the parietal cells that contain H+/K+-ATPase
in their luminal membrane, while the chief cells enrich the glandular secretion
with pepsinogen. The high concentration of H+ (pH 1.0–2.0) denatures
the food proteins and activates pepsinogens into pepsins which are
endopeptidases and split certain peptide bindings in food proteins.
The regulation of gastric secretion is
achieved through neural, endocrine, paracrine, and autocrine mechanisms. Stimulation is provided by acetylcholine, the
postganglionic transmitter of vagal parasympathetic fibers (muscarinic M1 receptors
and via neurons stimulating gastrin release by gastrin-releasing peptide
[GRP]), gastrin(endocrine) originating from the G cells of the antrum, and
histamine (paracrine, H2 receptor), secreted by the ECL cells and
mast cells of the gastric wall. Inhibitors are secretin (endocrine)
from the small intestine, somatostatin (SIH; paracrine) as well as
prostaglandins (especially E2 and I2), transforming
growth factor α (TGF-α) and adenosine (all paracrines and
autocrines). The inhibition of gastric secretion by a high concentration of H+
ions in the gastric lumen is also an important regulatory mechanism.
Protection of the gastric and duodenal mucosa. Because the acid–pepsin mixture of gastric secretion denatures and
digests protein, the protein-containing wall of the stomach and duodenum has to
be protected from the harmful action of gastric juice. The following mechanisms
are involved in this:
a) A gel-like mucus film, 0.1–0.5mm thick,
protects the surface of the gastric epithelium. The mucus is secreted by epithelial
cells (and depolymerized by the pepsins so that it can then be dissolved).
b) The epithelium secretes HCO3
– ions that are enriched not only in the liquid layer directly over
the epithelium, but also diffuse into the mucus film, where they buffer H+
ions that have penetrated from the gastric lumen. Prostaglandins are
important stimulants of this HCO3 – secretion.
c) In addition, the epithelium itself (apical
cell membrane, tight junctions) has barrier properties that largely prevent the
penetration of H+ ions or can very effectively remove those H+ ions
that have already penetrated (Na+/H+ exchange carrier
only basolaterally). These properties are regulated, among others, by the
epidermal growth factor (EGF) contained in saliva and bound to receptors of the
apical epithelial membrane. Glutathione-dependent, antioxidative mechanisms are
also part of this cytoprotection.
d) Finally, good mucosal blood flow serves as the
last “line of defense” that, among other actions, quickly removes H+
ions and provides a supply of HCO3 – and substrates of energy
metabolism.
Epithelial repair and wound healing. The following mechanisms repair epithelial defects that occur despite
the protective factors listed above. The epithelial cells adjoining the defect
are flattened and close the gap through sideward migration along the basal
membrane. This restitution takes about 30 minutes.
Closing the gap by cell growth takes longer
(proliferation; → p. 4). EGF, TGF-α, insulin-like growth factor
(IGF-1), gastrin-releasing peptide (GRP), and gastrin stimulate this process.
When the epithelium is damaged, especially those cell types proliferate rapidly
that secrete an EGF-like growth factor.
If ultimately the basement membrane is also destroyed,
acute
wound healing processes are initiated: attraction of leukocytes and
macrophages; phagocytosis of necrotic cell residua; revascularization
(angiogenesis); regeneration of extracellular matrix as well as, after repair
of the basement membrane, epithelial closure by restitution and cell division.
The danger of epithelial arrosion and subsequent ulcer
formation exists whenever the protective and reparative mechanisms are weakened
and/or the chemical attack by the acid–pepsin mixture is too strong and
persists for too long. Gastric and duodenalulcers may thus have quite different
causes.
Infection with Helicobacter pylori (H. pylori) is the most common cause of ulcer. As a
consequence, administration of antibiotics has been shown to be the most efficacious
treatment in most ulcer patients not receiving nonsteroidal anti-inflammatory
drugs (NSAIDs; see below). H. pylori probably survives the acidic environment
of the mucus layer because it possesses a special urease. The bacterium uses
this to produce CO2 and NH3, and HCO3 –
and NH4+, respectively, and can thus itself buffer H+
ions in the surroundings. H. pylori is transmitted from person to person,
causing inflammation of the gastric mucosa. A gastic or duodenal ulcer is ten
times more likely to develop in such cases than if a person does not suffer
from gastritis of this kind. The primary cause of such an ulcer is a disorder
in the epithelium’s barrier function, brought about by the infection.
It is likely that, together with this ulcer formation due to the
infection, there is also an increased chemical attack, as by oxygen radicals
that are formed by the bacteria themselves, as well as by the leukocytes and
macrophages taking part in the immune response, or by pepsins, because H.
pylori stimulates pepsinogen secretion.
Helicobacter pylori (H. pylori) is
the most common cause of ulcer
The fact that infection of the gastric antrum also frequently leads to duodenal
ulcer is probably related to gastrin secretion being increased by the
infection. As a result, acid and pepsinogen liberation is raised and the
duodenal epithelium is exposed to an increased chemical attack. This causes
metaplasia of the epithelium, which in turn favors the embedding of H. pylori,
leading to duodenitis and increased metaplasia, etc.
A further common cause of ulcer isthe intake of NSAIDs, for example,
indomethacin, diclofenac, aspirin (especially in high doses). Their
anti-inflammatory and analgesic action is based mainly on their inhibitory
effect on cyclo-oxygenase, thus blocking prostaglandin synthesis (from
arachidonic acid). An undesirable effect of NSAIDs is that they systemically
block prostaglandin synthesis also in gastric and duodenal epithelia. This
decreases HCO3– secretion, on the one hand, and stops
inhibition of acid secretion, on the other. In addition, these drugs damage the
mucosa locally by nonionic diffusion into the mucosal cells (pH of gastric
juice << pKa’ of the NSAIDs). During intake of NSAIDs an acute ulcer may
thus develop after days or weeks, the inhibitory action of these drugs on
platelet aggregation raising the danger of bleeding from the ulcer.
Acute ulcers also occur if there is very severe
stress on the organism (stress ulcer), as after major surgery, extensive burns,
and multi-organ failure (“shock”). The main cause here is probably impaired
blood flow through the mucosa correlated with high plasma concentrationsof
cortisol.
Often psychogenic factors favor ulcer development. Strong emotional
stress without an outward “safety valve” (high cortisol levels) and/or
disturbed ability to cope with “normal” stress, for example, in one’s job, are
the usual causes. Psychogenically raised secretion of gastric acid and
pepsinogen, as well as stress-related bad habits (heavy smoking, antiheadache
tablets [NSAIDs], high-proof alcohol) often play a part.
Smoking is
a risk factor for ulcer development. A whole series of moderately effective
single factors seem to add up here. Alcohol in large quantities or in high concentration damages the mucosa,
while moderate drinking of wine and beer increases gastric secretion through
their nonalcoholic components.
Rare
causes of ulcer are tumors that autonomically
secrete gastrin (gastrinoma, Zollinger–Ellison syndrome), systemic
mastocytosis, or basophilia with a high plasma histamine concentration.
Apart from antibiotics (see above) and (rarely necessary) surgical
intervention, the treatment of ulcer consists of lowering acid and pepsinogen
secretion by blocking H2 and M1 receptors and/or of H+/K+
- ATPase. Treatment with antacids acts
partly by buffering the pH in the lumen, but also has further, as yet not fully
understood, effects on the mucosa.
Jaundice (Icterus)
Jaundice (i.e., icterus), which results from an abnormally high
accumulation of bilirubin in the blood, is a yellowish discoloration to the
skin and deep tissues.
The normal plasma concentration of bilirubin is maximally 17µmol/L. If
it rises to more than 30 µmol/L, the
sclera become yellow; if the concentration rises further, the skin turns
yellow as well (jaundice [icterus]). Because normal skin has a yellow cast, the
early signs of jaundice often are difficult to detect, especially in
persons with dark skin. Bilirubin has a special affinity for elastic
tissue. The sclera of the eye, which contains considerable elastic fibers,
usually is one of the first structures in which jaundice can be detected.
The common causes of prehepatic,
hepatic, and posthepatic jaundice
Several
forms can be distinguished:
- Prehepatic
jaundice is the result of increased bilirubin production, for example,
in hemolysis (hemolytic anemia, toxins), inadequate erythropoiesis (e.g.,
megaloblastic anemia), massive transfusion (transfused erythrocytes are
short-lived), or absorption of large hematomas. In all these conditions
unconjugated (indirect reacting) bilirubin in plasma is increased.
The major cause of prehepatic jaundice is excessive hemolysis of red
blood cells. Hemolytic jaundice occurs when red blood cells are destroyed at a
rate in excess of the liver’s ability to remove the bilirubin from the blood.
It may follow a hemolytic blood transfusion reaction or may occur in diseases
such as hereditary spherocytosis, in which the red cell membranes are
defective, or in hemolytic disease of the newborn. Neonatal hyperbilirubinemia
results in an increased production of bilirubin in newborn infants and their
limited ability to excrete it. Premature infants are at particular risk because
their red cells have a shorter life span and higher turnover rate. In
prehepatic jaundice, there is mild jaundice, the unconjugated bilirubin is
elevated, the stools are of normal color, and there is no bilirubin in the
urine.
- Intrahepatic
jaundice is caused by a specific defect of bilirubin uptake in the
liver cells (Gilbert syndrome Meulengracht), conjugation
(neonatal jaundice, Crigler–Najjar syndrome), or secretion of bilirubin in the bile
canaliculi (Dubin–Johnson syndrome, Rotor syndrome).
In
the first two defects it is mainly the unconjugated plasma bilirubin that is
increased; in the secretion type it is the conjugated bilirubin that is
increased. All three steps may be affected in liver diseases and disorders,for
example, in viral hepatitis, alcohol abuse, drug side effects (e.g., isoniazid,
phenytoin, halothane), liver congestion (e.g., right heart failure), sepsis
(endotoxins), or poisoning (e.g., the Amanita phalloides mushroom).
Intrahepatic or hepatocellular jaundice is caused by disorders that
directly affect the ability of the liver to remove bilirubin from the blood or
conjugate it so it can be eliminated in the bile. Liver diseases such as
hepatitis and cirrhosis are the most common causes of intrahepatic jaundice.
Intrahepatic jaundice usually interferes with all phases of bilirubin
metabolism—uptake, conjugation, and excretion. Both conjugated and unconjugated
bilirubin are elevated and the urine often is dark because of the presence of
bilirubin.
-
In posthepatic
jaundice the extrahepatic bile ducts are blocked, in particular by gallstones,
tumors (e.g., carcinoma of the head of the pancreas), or in cholangitis or
pancreatitis. In these conditions it is particularly conjugated bilirubin that
is increased.
Posthepatic or obstructive jaundice, also called cholestatic jaundice,
occurs when bile flow is obstructed between the liver and the intestine.
Among the causes of posthepatic jaundice are strictures of the bile duct,
gallstones, and tumors of the bile duct or the pancreas. Conjugated bilirubin
levels usually are elevated; the stools are clay colored because of the lack of
bilirubin in the bile; the urine is dark; the levels of serum alkaline
phosphatase are markedly elevated; and the aminotransferase levels are slightly
increased. Blood levels of bile acids often are elevated in obstructive
jaundice. As the bile acids accumulate in the blood, pruritus develops. A
history of pruritus preceding jaundice is common in obstructive jaundice.
Jaundice
The types of Jaundice
Cholestasis
Cholestasis, blockage of bile flow, is due to either intrahepatic
disorders, for example, cystic fibrosis, granulomatosis,
drug side effects (e.g., allopurinol, sulfonamides), high estrogen
concentration (pregnancy, contraceptive pill), graft versus host–reaction after
transplantation, or, secondarily, extrahepatic bile duct occlusion.
In cholestasis the bile canaliculi are enlarged, the fluidity of the
canalicular cell membrane is decreased (cholesterol embedding, bile salt
effect), their brush border is deformed (or totally absent) and the function of
the cytoskeleton, including canalicular motility, is disrupted. In addition,
one of the two ATP-driven bile salt carriers, which are meant for the
canalicular membrane, is falsely incorporated in the basolateral membrane in
cholestasis. In turn, retained bile salts increase the permeability of the
tight junctions and reduce mitochondrial ATP synthesis. However, it is
difficult to define which of these abnormalities is the cause and which the
consequence of cholestasis. Some drugs (e.g., cyclosporin A) have a cholestatic
action by inhibiting the bile salt carrier, and estradiol, because it inhibits
Na+-K+-ATPase and reduces membrane fluidity.
Most of the consequences of cholestasis are a result of retention of bile
components: bilirubin leads to jaundice (in neonates there is a danger of
kernicterus), cholesterol to cholesterol deposition in skin folds and tendons,
as well as in the cell membranes of liver, kidneys, and erythrocytes
(echinocytes, akanthocytes). The distressing pruritus (itching) is thought to
be caused by retained endorphins and/or bile salts. The absence of bile in the
intestine results in fatty stools and malabsorption. Finally, infection of
accumulated bile leads to cholangitis, which has its own cholestatic effect.
Portal Hypertension
Venous blood from stomach, intestines, spleen, pancreas, and gallbladder
passes via the portal vein to the liver where, in the sinusoids after mixture
with oxygen-rich blood of the hepatic artery, it comes into close contact with
the hepatocytes. About 15% of cardiac output flows through the liver, yet its
resistance to flow is so low that the normal portal vein pressure is only 4–8
mmHg.
Obstruction of blood flow in
the portal circulation, with portal hypertension and diversion of blood flow
to
other venous channels, including the
gastric and esophageal veins
If the cross-sectional area of the liver’s vascular bed is restricted,
portal vein pressure rises and portal hypertension develops. Its causes can be
an increased resistance in the following vascular areas, although strict
separation into three forms of intrahepatic obstructions is not always present
or possible:
- Prehepatic: portal vein thrombosis;
- Posthepatic: right heart failure, constrictive pericarditis, etc.;
- Intrahepatic:
– presinusoidal: chronic hepatitis, primary biliary cirrhosis, granuloma
in schistosomiasis, tuberculosis, leukemia, etc.
–
sinusoidal: acute hepatitis, damage
from alcohol (fatty liver, cirrhosis), toxins, amyloidosis,
etc.
–
postsinusoidal: venous occlusive
disease of the venules and small veins; BuddChiari syndrome
(obstruction of the large hepatic veins).
Enlargement
of the hepatocytes (fat deposition, cell swelling, hyperplasia) and increased
production of etracellular matrix both contribute to sinusoidal obstructio n.
As the extracellular matrix also impairs the exchange of substances and gases
between sinusoids and hepatocytes, cell swelling is further increased. Amyloid
depositions can ave a similar obstructive effect. Finally, in acute hepatitis
and acute liver necrosis the sinusoidal space can also be obstructed by cell
debris.
Mechanisms of disturbed liver function related
to portal hypertension
Consequences
of portal hypertension.
Wherever
the site of obstruction, an increased portal vein pressure will lead to
disorders in the preceding organs (malabsorption, splenomegaly with anemia and
thrombocytopenia) as well as to blood flowing from abdominal organs via
vascular channels that by pass the liver. These portal bypass circuits use
collateral vessels that are normally thin-walled but are now greatly dilated
(formation of varices; “haemorrhoids” of the rectal venous plexus; caput
medusae
at
the paraumbilical veins). The enlarged esophageal veins are particularly in
danger of rupturing. This fact, especially together with thrombocytopenia (see
above) and a deficiency in clotting factors (reduced synthesis in a damaged
liver), can lead to massive bleeding that can be acutely life-threatening.
The vasodilators liberated in portal
hypertension (glucagon, VIP, substance P, prostacyclins, NO, etc.) also lead to
a fall in systemic blood pressure. This will cause a compensatory rise
incardiac output, resulting in hyperperfusion of the abdominal organs and the
collateral (bypass) circuits.
Liver function is usually unimpaired in
prehepatic and presinusoidal obstruction, because blood supply is assured
through a compensatory increase in flow from the hepatic artery. Still, in
sinusoidal, postsinusoidal, and posthepatic obstruction liver damage is usually
the cause and then in part also the result of the obstruction. As a
consequence, drainage of protein-rich hepatic lymph is impaired and the
increased portal pressure, sometimes in synergy with a reduction in the
plasma’s osmotic pressure due to liver damage (hypoalbuminemia), pushes a
protein-rich fluid into the abdominal cavity, i.e., ascites develops. This
causes secondary hyperaldosteronism that results in an increase in
extracellular volume.
As blood from the intestine bypasses
the liver, toxic substances (NH3, biogenicamines, short-chain fatty
acids, etc.) that are normally extracted from portal blood by the liver cells
reach the central nervous system, among other organs, so that portalsystemic
(“hepatic”) encephalopathy develops.
Causes and Consequences of Portal
Hypertension
Ascites. Ascites
occurs when the amount of fluid in the peritoneal cavity is increased and is a
late-stage manifestation of cirrhosis and portal hypertension. It is not uncommon
for persons with advanced cirrhosis to present with an accumulation of
Although the mechanisms responsible for the development of ascites are
not completely understood, several factors seem to contribute to fluid
accumulation, including an increase in capillary pressure caused by portal
hypertension and obstruction of venous flow through the liver, salt and
water retention by the kidney, and decreased colloidal osmotic pressure caused
by impaired synthesis of albumin by the liver.
Treatment of ascites usually focuses on dietary restriction of sodium
and administration of diuretics. Water intake also may need to be restricted.
Because of the many limitations in sodium restriction, the use of diuretics has
become the mainstay of treatment for ascites. Oral potassium supplements often
are given to prevent hypokalemia. The upright position is associated with the
activation of the renin-angiotensin-aldosterone system; therefore, bed rest may
be recommended for persons with a large amount of ascites. Large-volume
paracentesis (removal of
Ascites
Splenomegaly.
The spleen enlarges progressively in portal hypertension because of
shunting of blood into the splenic vein. The enlarged spleen often gives rise
to sequestering of significant numbers of blood elements and development of
a syndrome known as hypersplenism. Hypersplenism is characterized by a decrease
in the life span and a subsequent decrease in all the formed elements of the
blood, leading to anemia, thrombocytopenia, and leukopenia. The person with
thrombocytopenia is subject to purpura, easy bruising, hematuria, and abnormal
menstrual bleeding, and is vulnerable to bleeding from the esophagus and other
segments of the gastrointestinal tract.
Liver Failure
Causes of acute liver failure are poisoning and inflammation, for
example, fulminant cholangitis or viral hepatitis (especially in hepatitis B
and E). The causes of chronic liver failure that is accompanied by fibrosis
(cirrhosis) of the liver are:
–
inflammation, for example, chronic
persistent viral hepatitis;
–
alcohol abuse, the most common cause;
–
in susceptible patients, side effects
of drugs, for example, folic acid antagonists, phenylbutazone;
– cardiovascular causes of impairment of venous return, for example, in
right heart failure;
– a number of inherited diseases, for example, glycogen storage
diseases, Wilson’s disease, galactosemia, hemochromatosis, α1-antitrypsin
deficiency;
–
intrahepatic or posthepatic
cholestasis for prolonged periods, for example, in cystic fibrosis, a stone in
the common bile duct, or tumors.
Alterations in liver function and
manifestations of liver failure
The most serious consequences of liver failure
are:
–
Protein synthesis in the liver is
reduced. This can lead to hypoalbuminemia that may result in ascites, i.e., an accumulation
of extracellular fluid in the abdominal cavity, and other forms of edema.
Plasma volume is reduced as a result, secondary hyperaldosteronism develops
causing hypokalemia, which in turn encourages alkalosis. In addition, the
reduced ability of the liver to synthesize causes a fall in the plasma
concentration of clotting factors.
–
Cholestasis occurs, producing not
only liver damage but also aggravating any bleeding tendency, because the lack
of bile salts decreases micellar formation and with it the absorption of
vitamin K from the intestine, so that γ-carboxylation of the vitamin
K-dependent clotting factors prothrombin (II), VII, IX, and X is reduced.
–
Portal hypertension develops and may make
the ascites worse because of lymphatic flow impairment. It may cause
thrombocytopenia resulting from splenomegaly, and may lead to the development
of clotting factors, thrombocytopenia, and varices are likely to cause severe
bleeding. Finally, portal hypertension can cause an exudative enteropathy. This
will increase the ascites due to loss of albumin from the plasma, while at the
same time favoring bacteria in the large intestine being “fed” with proteins
that have passed into the intestinal lumen, and thus increasing the liberation
of ammonium, which is toxic to the brain.
–
The hyperammonemia, which is partly
responsible for the encephalopathy (apathy, memory gaps, tremor, and ultimately
liver coma) is increased because.
1)
gastrointestinal bleeding also
contributes to an increased supply of proteins to the colon;
2)
the failing liver is no longer
sufficiently able to convert ammonium (NH3NH4+ )
to urea;
3)
the above-mentioned hypokalemia
causes an intracellular acidosis which activates ammonium formation in the
cells of the proximal tubules and at the same time causes a systemic alkalosis.
A respiratory component is added to the latter if the patient hyperventilates
due to the encephalopathy.
Further
substances that are toxic to the brain bypass the liver in portal hypertension
and are therefore not extracted by it as would normally be the case. Those
substances, such as amines, phenols, and short-chain fatty acids, are also
involved in the encephalopathy. Lastly, the brain produces “false transmitters”
(e.g., serotonin) from the aromatic amino acids, of which there are increased
amounts in plasma when liver failure occurs. These transmitters probably play a
part in the development of the encephalopathy.
Hepatic encephalopathy refers to the
totality of central nervous system manifestations of liver failure. It is
characterized by neural disturbances ranging from a lack of mental alertness to
confusion, coma, and convulsions. A very early sign of hepatic encephalopathy
is a flapping tremor called asterixis. Various degrees of memory loss may
occur, coupled with personality changes such as euphoria, irritability,
anxiety, and lack of concern about personal appearance and self. Speech may be
impaired, and the patient may be unable to perform certain purposeful movements.
The encephalopathy may progress to decerebrate rigidity and then to a terminal
deep coma. Although the cause of hepatic encephalopathy is unknown, the
accumulation of neurotoxins, which appear in the blood because the liver has
lost its detoxifying capacity, is believed to be a factor. Hepatic
encephalopathy develops in approximately 10% of persons with portosystemic
shunts. One of the suspected neurotoxins is ammonia. A particularly important
function of the liver is the conversion of ammonia, a by-product of protein and
amino acid metabolism, to urea. The ammonium ion is produced in abundance in
the intestinal tract, particularly in the colon, by the bacterial degradation
of luminal proteins and amino acids. Normally, these ammonium ions diffuse into
the portal blood and are transported to the liver, where they are converted to
urea before entering the general circulation. When the blood from the intestine
bypasses the liver or the liver is unable to convert ammonia to urea, ammonia
moves directly into the general circulation and then into the cerebral
circulation. Hepatic encephalopathy may become worse after a large pro-
tein
meal or gastrointestinal tract bleeding.
Hematologic Disorders.
Liver failure can cause anemia, thrombocytopenia, coagulation defects, and
leukopenia. Anemia may be caused by blood loss, excessive red blood cell
destruction, and impaired formation of red blood cells. A folic acid deficiency
may lead to severe megaloblastic anemia. Changes in the lipid composition of
the red cell membrane increase hemolysis. Because factors V, VII, IX, and X,
prothrombin, and fibrinogen are synthesized by the liver, their decline
in liver disease contributes to bleeding disorders. Malabsorption of the
fat-soluble vitamin K contributes further to the impaired synthesis of these
clotting factors.
Endocrine Disorders. The liver
metabolizes the steroid hormones. Endocrine disorders, particularly
disturbances in gonadal function, are common accompaniments of cirrhosis and
liver failure. Women may have menstrual irregularities (usually amenorrhea),
loss of libido, and sterility. In men, testosterone levels usually fall, the
testes atrophy, and loss of libido, impotence, and gynecomastia occur. A
decrease in aldosterone metabolism may contribute to salt and water retention
by the kidney, along with a lowering of serum potassium resulting from
increased elimination of potassium.
Skin Disorders. Liver failure brings
on numerous skin disorders. These lesions, called variously vascular spiders,
telangiectases, spider angiomas, and spider nevi, are seen most often in the
upper half of the body. They consist of a central pulsating arteriole from
which smaller vessels radiate. Palmar erythema is redness of the palms,
probably caused by increased blood flow from higher cardiac output.
Clubbing of the fingers may be seen in persons with cirrhosis. Jaundice
usually is a late manifestation of liver failure.
Kidney function is impaired, giving
rise to the hepatorenal syndrome. The hepatorenal syndrome refers to a
functional
state of renal failure sometimes seen during the terminal stages of liver
failure with ascites. It is characterized by progressive azotemia, increased
serum creatinine levels, and oliguria. Although the basic cause is unknown, a
decrease in renal blood flow is believed to play a part. Ultimately, when
renal failure is superimposed on liver failure, azotemia and elevated levels of
blood ammonia occur; this condition is thought to contribute to hepatic
encephalopathy and coma.
Fibrosis and Cirrhosis of the Liver
Causes and Consequences of Liver Failure
Treatment.
The treatment of liver failure is directed toward
eliminating alcohol intake when the condition is caused by alcoholic cirrhosis;
preventing infections; providing sufficient carbohydrates and calories to
prevent protein breakdown; correcting fluid and electrolyte imbalances,
particularly hypokalemia; and decreasing ammonia production in the
gastrointestinal tract by controlling protein intake. In many cases, liver transplantation
remains the only effective treatment.